Citations

Clear

2416 citation(s) found for "Yu, Jason L".

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients
Chemaly, Roy F. , Dadwal, Sanjeet , Bergeron, Anne , Kim, Yae‐Jean , Pipavath, Sudhakar , Blanchard, Élodie , Winston, Drew J., Stiff, Patrick J. , Zuckerman, Tsila , Rahav, Galia , Small, Catherine B. , Mullane, Kathleen M. , Patron, Roberto L. , Lee, Dong‐Gun , Hirsch, Hans H. , McKevitt, Matt, Jordan, Robert , Guo, Ying , German, Polina , Porter, Danielle , Gossage, David, Watkins, Timothy R., Marty, Francisco M. , Chien, Jason W. , Ljungman, Per , Cheng, Guang‐Shing , Limaye, Ajit P. , Lachance, Silvy , Waghmare, Alpana , Boeckh, Michael

Mayo Clinic

Clinical Infectious Diseases | December 3, 2019 | Volume: 71 | Issue: 11 | Pages: 2777-2786

10.1093/cid/ciz1166 | PMID 31793991 Get It

AbstractBackgroundHematopoietic-cell transplant (HCT) recipients are at risk for severe respiratory syncytial virus (RSV) infection. We evaluated the RSV fusion inhibitor presatovir in a randomized, double-blind, Phase II trial in HCT recipients with RSV upper respiratory tract infections.MethodsPatients were stratified by lymphopenia (<200/µL) and ribavirin use; were randomized, stratified by lymphopenia (<200/μL) and ribavirin use, to receive oral presatovir at 200 mg or a placebo on Days 1, 5, 9, 13, and 17, and were followed through Day 28. The coprimary efficacy endpoints were the time-weighted average change in the nasal RSV viral load between Days 1 and 9 and the proportion of patients developing lower respiratory tract complications (LRTCs) through Day 28.ResultsFrom 23 January 2015 to 16 June 2017, 189 patients were randomly assigned to treatment (96 to presatovir and 93 to the placebo). Presatovir treatment, compared with the placebo treatment, did not significantly affect (prespecified α = 0.01) a time-weighted average decline in the RSV viral load from Day 1 to 9 (treatment difference, −0.33 log10 copies/mL; 95% confidence interval [CI] −.64 to −.02 log10 copies/mL; P = .040) or the progression to LRTC (11.2% vs 19.5%, respectively; odds ratio, 0.50; 95% CI, .22–1.18; P = .11). In a post hoc analysis among patients with lymphopenia, presatovir decreased LRTC development by Day 28 (2/15 [13.3%] vs 9/14 [64.3%], respectively; P = .008), compared with the placebo. Adverse events were similar for patients receiving presatovir and the placebo.ConclusionsPresatovir had a favorable safety profile in adult HCT recipients with RSV but did not achieve the coprimary endpoints. Exploratory analyses suggest an antiviral effect among patients with lymphopenia.Clinical Trials RegistrationNCT02254408; EUDRA-CT#2014-002474-36.
Screening Postoperative Hemoglobin after Robot-Assisted Radical Prostatectomy—Frequently Used, but Is It Necessary?
Joseph, Jason , Glasgow, Amy E. , Carlson, Rachel E. , Frank, Igor, Tollefson, Matthew K. , Boorjian, Stephen A. , Thompson, R. Houston, Karnes, R. Jeffrey , Gettman, Matthew T., Joseph, Jason P, Habermann, Elizabeth B.

Mayo Clinic

Urology Practice | December 2, 2019 | Volume: 7 | Issue: 6 | Pages: 554-558

10.1097/upj.0000000000000121 | PMID 37287152 Get It

Improved pulmonary 129 Xe ventilation imaging via 3D‐spiral UTE MRI
Willmering, Matthew M. , Niedbalski, Peter , Wang, Hui , Walkup, Laura L. , Robison, Ryan K. , Pipe, James G. , Woods, Jason C. , Niedbalski, Peter J , Cleveland, Zackary I.

Mayo Clinic

Magnetic Resonance in Medicine | December 2, 2019 | Volume: 84 | Issue: 1 | Pages: 312-320

10.1002/mrm.28114 | PMID 31788858 Get It

Purpose Hyperpolarized 129 Xe MRI characterizes regional lung ventilation in a variety of disease populations, with high sensitivity to airway obstruction in early disease. However, ventilation images are usually limited to a single breath‐hold and most‐often acquired using gradient‐recalled echo sequences with thick slices (~10‐15 mm), which increases partial‐volume effects, limits ability to observe small defects, and suffers from imperfect slice selection. We demonstrate higher‐resolution ventilation images, in shorter breath‐holds, using FLORET (Fermat Looped ORthogonally Encoded Trajectories), a center‐out 3D‐spiral UTE sequence. Methods In vivo human adult ( N = 4; 2 healthy, 2 with cystic fibrosis) 129 Xe images were acquired using 2D gradient‐recalled echo, 3D radial, and FLORET. Each sequence was acquired at its highest possible resolution within a 16‐second breath‐hold with a minimum voxel dimension of 3 mm. Images were compared using 129 Xe ventilation defect percentage, SNR, similarity coefficients, and vasculature cross‐sections. Results The FLORET sequence obtained relative normalized SNR, 40% greater than 2D gradient‐recalled echo ( P = .012) and 26% greater than 3D radial ( P = .067). Moreover, the FLORET images were acquired with 3‐fold‐higher nominal resolution in a 15% shorter breath‐hold. Finally, vasculature was less prominent in FLORET, likely due to diminished susceptibility‐induced dephasing at shorter TEs afforded by UTE sequences. Conclusion The FLORET sequence yields higher SNR for a given resolution with a shorter breath‐hold than traditional ventilation imaging techniques. This sequence more accurately measures ventilation abnormalities and enables reduced scan times in patients with poor compliance and severe lung disease.
Anti–PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma
Ene, Chibawanye , Kreuser, Shannon , Jung, M. Katherine , Zhang, Huajia , Moyes, Kara White, Szulzewsky, Frank , Barber, Jason , Cimino, Patrick J. , Wirsching, Hans‐Georg , Patel, Anoop P. , Kong, Paul , Woodiwiss, Timothy , Durfy, Sharon , Houghton, A. McGarry, Crane, Courtney A., Jung, Miyeon, Cimino, Patrick J , Jung, Miyeon, Arora, Sonali , Pierce, Robert Hamilton , Parney, Ian F. , Holland, Eric C.

Mayo Clinic

Neuro-Oncology | December 2, 2019 | Volume: 22 | Issue: 5 | Pages: 639-651

10.1093/neuonc/noz226 | PMID 31793634 Get It

Abstract Background Most glioblastomas recur near prior radiation treatment sites. Future clinical success will require achieving and optimizing an “abscopal effect,” whereby unirradiated neoplastic cells outside treatment sites are recognized and attacked by the immune system. Radiation combined with anti–programmed cell death ligand 1 (PD-L1) demonstrated modest efficacy in phase II human glioblastoma clinical trials, but the mechanism and relevance of the abscopal effect during this response remain unknown. Methods We modified an immune-competent, genetically driven mouse glioma model (forced platelet derived growth factor [PDGF] expression + phosphatase and tensin homolog loss) where a portion of the tumor burden is irradiated (PDGF) and another unirradiated luciferase-expressing tumor (PDGF + luciferase) is used as a readout of the abscopal effect following systemic anti–PD-L1 immunotherapy. We assessed relevance of tumor neoepitope during the abscopal response by inducing expression of epidermal growth factor receptor variant III (EGFRvIII) (PDGF + EGFRvIII). Statistical tests were two-sided. Results Following radiation of one lesion, anti–PD-L1 immunotherapy enhanced the abscopal response to the unirradiated lesion. In PDGF-driven gliomas without tumor neoepitope (PDGF + luciferase, n = 8), the abscopal response occurred via anti–PD-L1 driven, extracellular signal-regulated kinase–mediated, bone marrow–derived macrophage phagocytosis of adjacent unirradiated tumor cells, with modest survival implications (median survival 41 days vs radiation alone 37.5 days, P = 0.03). In PDGF-driven gliomas with tumor neoepitope (PDGF + EGFRvIII, n = 8), anti–PD-L1 enhanced abscopal response was associated with macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs radiation alone 28 days, P = 0.001). Conclusion Our results indicate that anti–PD-L1 immunotherapy enhances a radiation- induced abscopal response via canonical T-cell activation and direct macrophage activation in glioblastoma.
Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion
Kotecha, Rupesh , Sahgal, Arjun , Rubens, Muni , Salles, Antônio De, Fariselli, Laura , Pollock, Bruce E. , Ma, Lijun , Paddick, Ian , Régis, Jean , Sheehan, Jason P. , Yomo, Shoji , Paddick, Ian , Levivier, Marc , Suh, John H.

Mayo Clinic

Neuro-Oncology | December 2, 2019 | Volume: 22 | Issue: 3 | Pages: 318-332

10.1093/neuonc/noz225 | PMID 31790121 Get It

Abstract Background This systematic review reports on outcomes and toxicities following stereotactic radiosurgery (SRS) for non-functioning pituitary adenomas (NFAs) and presents consensus opinions regarding appropriate patient management. Methods Using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a systematic review was performed from articles of ≥10 patients with NFAs published prior to May 2018 from the Medline database using the key words “radiosurgery” and “pituitary” and/or “adenoma.” Weighted random effects models were used to calculate pooled outcome estimates. Results Of the 678 abstracts reviewed, 35 full-text articles were included describing the outcomes of 2671 patients treated between 1971 and 2017 with either single fraction SRS or hypofractionated stereotactic radiotherapy (HSRT). All studies were retrospective (level IV evidence). SRS was used in 27 studies (median dose: 15 Gy, range: 5–35 Gy) and HSRT in 8 studies (median total dose: 21 Gy, range: 12–25 Gy, delivered in 3–5 fractions). The 5-year random effects local control estimate after SRS was 94% (95% CI: 93.0–96.0%) and 97.0% (95% CI: 93.0–98.0%) after HSRT. The 10-year local control random effects estimate after SRS was 83.0% (95% CI: 77.0–88.0%). Post-SRS hypopituitarism was the most common treatment-related toxicity observed, with a random effects estimate of 21.0% (95% CI: 15.0–27.0%), whereas visual dysfunction or other cranial nerve injuries were uncommon (range: 0–7%). Conclusions SRS is an effective and safe treatment for patients with NFAs. Encouraging short-term data support HSRT for select patients, and mature outcomes are needed before definitive recommendations can be made. Clinical practice opinions were developed on behalf of the International Stereotactic Radiosurgery Society (ISRS).
Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.
Tine, Brian Andrew Van, Hu, James , Schuetze, Scott M. , Attia, Steven , Priebat, Dennis A., Okuno, Scott H. , Riedel, Richard F. , Movva, Sujana , Baker, Laurence H. , Maki, Robert G. , Patel, Shreyaskumar , Tawbi, Hussein, Maki, Robert G , Riedel, Richard F , Burgess, Melissa , Roszik, Jason , D'Angelo, Sandra P , Davis, Lara E. , Reed, Damon R. , Reinke, Denise K. , Butterfield, Lisa Helene

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 60-60

10.1200/jco.2017.35.7_suppl.60 Get It

60 Background: The activity of the anti-PD-1 antibody P in pts with advanced STS was evaluated in a prospective multicenter Phase II study conducted by the Sarcoma Alliance for Research through Collaboration (SARC). SARC028 enrolled 40 patients with advanced soft tissue sarcoma. Pembro had an ORR of 19% and PFS rate at 12 weeks of 55%, suggesting clinical activity. We investigated biomarkers of response to P. Methods: The primary endpoint was Objective Response Rate (ORR) by RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival, and biomarkers of response in blood and tumor. Pre- and on-treatment biopsies were required and obtained from over 90% and 72% of pts respectively. Serum was obtained from all pts at baseline and at multiple time points on therapy (pre-, week 8, and every 12 weeks). Sera were examined for candidate circulating biomarkers by Affymetrix Luminex platform array, including PD-L2. To determine whether there is a statistically significant difference between different conditions, we used Mann-Whitney and two-tailed t tests. Log-rank p-values in Kaplan-Meier survival analyses were calculated using the "survival" R package. Results: Forty pts with STS were enrolled into 4 cohorts (10 each) based on histological subtype including undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (LPS), synovial sarcoma (SS), and leiomyosarcoma (LMS). 4 pts with UPS, 2 pts with LPS, and one pt with SS achieved a response. Six of seven responses were durable at the time of this analysis. Circulating levels at baseline or after therapy of PD-1, PD-L1, 4-1BB, IDO, BTLA, CTLA-4, LAG-3, and TIM-3 did not correlate with outcome. However, pre-treatment and week 8 PD-L2 levels correlated best with clinical outcome: high PD-L2 levels were associated with better PFS (p=0.019) in STS. Conclusions: P has clinical activity in specific histologic subtypes of STS, namely UPS and LPS. Pre-treatment circulating PD-L2 levels correlated with progression-free survival and is a novel and promising predictor of improved clinical outcome of PD-1 therapy in STS.
Information Extraction for Populating Lung Cancer Clinical Research Data
Wang, Liwei , Luo, Lei , Wang, Yanshan , Wampfler, Jason A. , Wang, Yanshan , Yang, Ping , Liu, Hongfang

Mayo Clinic

2019 IEEE International Conference on Healthcare Informatics (ICHI) | November 25, 2019 | Volume: No volume available | Issue: No issue available | Pages: 1-2

10.1109/ichi.2019.8904601 | PMID 32537571 Get It

Refining the adipose progenitor cell landscape in healthy and obese visceral adipose tissue using single-cell gene expression profiling
Cho, Dong Seong , Lee, Bolim, Doles, Jason D. , Doles, Jason D , Lee, Bolim

Mayo Clinic

Life Science Alliance | November 25, 2019 | Volume: 2 | Issue: 6 | Pages: e201900561

10.26508/lsa.201900561 | PMID 31767614 Get It

Obesity is a serious health concern and is associated with a reduced quality of life and a number of chronic diseases, including diabetes, heart disease, stroke, and cancer. With obesity rates on the rise worldwide, adipose tissue biology has become a top biomedical research priority. Despite steady growth in obesity-related research, more investigation into the basic biology of adipose tissue is needed to drive innovative solutions aiming to curtail the obesity epidemic. Adipose progenitor cells (APCs) play a central role in adipose tissue homeostasis and coordinate adipose tissue expansion and remodeling. Although APCs are well studied, defining and characterizing APC subsets remains ambiguous because of ill-defined cellular heterogeneity within this cellular compartment. In this study, we used single-cell RNA sequencing to create a cellular atlas of APC heterogeneity in mouse visceral adipose tissue. Our analysis identified two distinct populations of adipose tissue–derived stem cells (ASCs) and three distinct populations of preadipocytes (PAs). We identified novel cell surface markers that, when used in combination with traditional ASC and preadipocyte markers, could discriminate between these APC subpopulations by flow cytometry. Prospective isolation and molecular characterization of these APC subpopulations confirmed single-cell RNA sequencing gene expression signatures, and ex vivo culture revealed differential expansion/differentiation capabilities. Obese visceral adipose tissue featured relative expansion of less mature ASC and PA subpopulations, and expression analyses revealed major obesity-associated signaling alterations within each APC subpopulation. Taken together, our study highlights cellular and transcriptional heterogeneity within the APC pool, provides new tools to prospectively isolate and study these novel subpopulations, and underscores the importance of considering APC diversity when studying the etiology of obesity.
Using Digital Pathology to Understand Epithelial Characteristics of Benign Breast Disease among Women Undergoing Diagnostic Image-Guided Breast Biopsy
Puvanesarajah, Samantha , Fan, Shaoqi , Pfeiffer, Ruth M. , Olsson, Linnea T. , Hada, Manila , Kirk, Erin L. , Vacek, Pamela M. , Weaver, Donald L. , Shepherd, John , Mahmoudzadeh, Amir Pasha , Johnson, Jason M. , Hewitt, Stephen M. , Herschorn, Sally D. , Gierach, Gretchen L. , Puvanesarajah, Samantha , Pfeiffer, Ruth M , Olsson, Linnea T , Mahmoudzadeh, Amir , Herschorn, Sally D , Gierach, Gretchen L , Mullooly, Maeve , Wang, Jeff , Malkov, Serghei , Sherman, Mark E. , Troester, Melissa A.

Mayo Clinic

Cancer Prevention Research | November 20, 2019 | Volume: 12 | Issue: 12 | Pages: 861-870

10.1158/1940-6207.capr-19-0120 | PMID 31645342 Get It

Abstract Delayed terminal duct lobular unit (TDLU) involution is associated with elevated mammographic breast density (MD). Both are independent breast cancer risk factors among women with benign breast disease (BBD). Prior digital analyses of normal breast tissues revealed that epithelial nuclear density (END) and TDLU involution are inversely correlated. Accordingly, we examined associations of END, TDLU involution, and MD in BBD clinical biopsies. This study included digitized images of 262 representative image-guided hematoxylin and eosin–stained biopsies from 224 women diagnosed with BBD, enrolled within the cross-sectional BREAST-Stamp project that were visually assessed for TDLU involution (TDLU count/100 mm2, median TDLU span and median acini count per TDLU). A digital algorithm estimated nuclei count per unit epithelial area, or END. Single X-ray absorptiometry of prebiopsy ipsilateral craniocaudal digital mammograms measured global and localized MD surrounding the biopsy region. Adjusted ordinal logistic regression models assessed relationships between tertiles of TDLU and END measures. Analysis of covariance examined mean differences in MD across END tertiles. TDLU measures were positively associated with increasing END tertiles [TDLU count/100 mm2, ORT3vsT1: 3.42, 95% confidence interval (CI), 1.87–6.28; acini count/TDLUT3vsT1, OR: 2.40, 95% CI, 1.39–4.15]. END was significantly associated with localized, but not, global MD. Relationships were most apparent among patients with nonproliferative BBD. These findings suggest that quantitative END reflects different but complementary information to the histologic information captured by visual TDLU and radiologic MD measures and merits continued evaluation in assessing cellularity of breast parenchyma to understand the etiology of BBD.
Peri‐procedural Management of Implanted Spinal Cord Stimulators in Patients Undergoing Radiofrequency Ablation: A Case Report and Manufacturer‐Specific Recommendations
Abdullah, Newaj , Muir, Casey , Eldrige, Jason S. , Pingree, Matthew J. , Hagedorn, Jonathan M. , Hagedorn, Jonathan M

Mayo Clinic

Pain Practice | November 20, 2019 | Volume: 20 | Issue: 4 | Pages: 405-411

10.1111/papr.12860 | PMID 31746540 Get It

Abstract IntroductionRadiofrequency ablation (RFA) and spinal cord stimulation (SCS) are 2 common modalities used in management of various pain conditions. RFA generates heat and an electromagnetic field that can theoretically interfere with the functionality and longevity of the SCS device. This is problematic for patients who need RFA and have previously undergone implantation of an SCS device.Case DescriptionWe present a case highlighting the safe use of bipolar RFA in a patient who had previously undergone implantation of a cervical SCS device.DiscussionWe also present device‐specific industry guidelines and recommendations for performing RFA in patients following SCS device implantation.